Oncothyreon Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 54   

Articles published

ONTY 2.06 -0.17 (-7.83%)
price chart
Best Biotech Stocks To Buy Now [Neuralstem, Inc., Oncothyreon Inc (USA ...
In fact, Tremblay believes that strong growth in prescription drug sales, growth in FDA drug approvals, increasing orphan drug development, and an aging U.S. population are all reasons to invest in biotech stocks now. Now, penny stock investing is ...
Biotech Stocks in Trouble- Oncothyreon Inc (USA) (NASDAQ:ONTY), Tekmira ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) [Trend Analysis] plunged in last trading session following the company's tecemotide lung cancer treatment failed to show any effects in a trial in Japan.
Related articles »  
Momentum Stocks in Focus - Control4 Corp (NASDAQ:CTRL), Oncothyreon Inc ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) declared that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York on Tuesday, Sept.
Stocks Buzz: Oncothyreon Inc (USA) (ONTY), Elbit Imaging Ltd (NASDAQ:EMITF ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) announced financial results for the 2ndquarter ended June 30, 2014. Loss from operations decreased to $7.8 million for the three months ended June 30, 2014 compared with $18.0 million for the comparable period ...
Top Decliners of this Morning: Elizabeth Arden, Inc. (RDEN), Oncothyreon Inc ...  Investor Wired
Related articles »  
Are These Stocks Strong Investment Options? Oncothyreon Inc (USA)(NASDAQ ...
Oncothyreon Inc (USA)(NASDAQ:ONTY) suffered a 17.27% decrease in value during yesterday's trading as the stock fell forty-eight cents to finish the day at a closing price of $2.30.
Related articles »  
Oncothyreon And Merck Develop Tecemodite
Oncothyreon Inc. (ONTY) announced today that Merck KGaA's (MRK) biopharmaceutical business, Merck Serono, will be developing its antigen-specific cancer immunotherapy, tecemotide (previously known as Stimuvax).
Merck to stop all tests with Oncothyreon cancer drug  Puget Sound Business Journal (Seattle) (blog)
Merck Discontinues Clinical Development Program of Tecemotide as a ...  MarketWatch
Related articles »  
Oncothyreon Inc. (ONTY) EMR 63325-009 Study Misses Primary Endpoint
Merck KGaA (NYSE: MRK), Darmstadt, Germany, has informed Oncothyreon Inc. (Nasdaq: ONTY) that a randomized Phase 1/2 study, EMR 63325-009, of tecemotide compared to placebo in Japanese patients with Stage III non-small cell lung cancer did not ...
Oncothyreon cancer drug test in Japan shows 'no treatment effect,' ...  Puget Sound Business Journal (Seattle) (blog)
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study  Zacks.com
Related articles »  
Stocks in Focus : TrueCar (NASDAQ:TRUE), Oncothyreon Inc (NASDAQ:ONTY ...
On SEP 3, TrueCar, Inc. (NASDAQ:TRUE), the negotiation-free car buying and selling platform, reported that the estimated average transaction price (ATP) for light vehicles in the U.S. was $31,610 in August 2014, up $751 (2.4 percent) from August 2013 ...
Mid-Day Movers ´┐ŻElizabeth Arden, Inc. (NASDAQ:RDEN),Oncothyreon Inc (USA ...
Elizabeth Arden, Inc. (NASDAQ:RDEN) announced financial results for its fourth fiscal quarter and year ended June 30, 2014.
Related articles »  
Morning Alert: Oncothyreon Inc (NASDAQ:ONTY), TG Therapeutics (NASDAQ ...
VCA Inc. (NASDAQ:WOOF), a leading animal healthcare company in the United States, will present at CL King's 12th Annual Best Ideas Conference on Tuesday, September 9, 2014, at the Omni Berkshire Place Hotel in New York City.